Subconjunctival Rituximab Administration for the Treatment of Scleritis

D. P.C. Vergouwen; J. C. Ten Berge; N. C. Naus-Postema; A. Rothova

doi:10.1080/09273948.2022.2029498

Subconjunctival Rituximab Administration for the Treatment of Scleritis

D. P.C. Vergouwen^*, J. C. Ten Berge, N. C. Naus-Postema, A. Rothova

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Citation (Scopus)

Abstract

Purpose: Scleritis is a sight-threatening inflammation, which is commonly accompanied by severe complications. Aggressive systemic immunosuppressive treatment, which is frequently needed, can be associated with serious complications, and might therefore be (temporarily) contraindicated. Methods: We report on the outcomes of three patients with severe, active, non-infectious scleritis, refractory or intolerant to systemic treatment, who received subconjunctival rituximab (RTX) injections. A dose of 2.5 to 7.5 mg was administered after topical anesthesia, and follow-up varied from 8 to 10 months. Results: Subconjunctival RTX showed minimal to no effect on subjective symptoms, clinical features and/or ultrasound images. No serious adverse effects occurred. Conclusion: Further studies are needed to assess the effect of local administration of RTX in scleritis, but our limited observation is not promising.

Original language	English
Pages (from-to)	1309-1311
Number of pages	3
Journal	Ocular Immunology and Inflammation
Volume	30
Issue number	6
Early online date	16 Feb 2022
DOIs	https://doi.org/10.1080/09273948.2022.2029498
Publication status	Published - 2022

Bibliographical note

Funding Information:
This work was supported by Stichting Lijf en Leven under Grant [number L&L/mon/19-007].

Publisher Copyright:
© 2022 Taylor & Francis Group, LLC.

Access to Document

10.1080/09273948.2022.2029498

Cite this

@article{3943f272034345abba76fe21545f173c,

title = "Subconjunctival Rituximab Administration for the Treatment of Scleritis",

abstract = "Purpose: Scleritis is a sight-threatening inflammation, which is commonly accompanied by severe complications. Aggressive systemic immunosuppressive treatment, which is frequently needed, can be associated with serious complications, and might therefore be (temporarily) contraindicated. Methods: We report on the outcomes of three patients with severe, active, non-infectious scleritis, refractory or intolerant to systemic treatment, who received subconjunctival rituximab (RTX) injections. A dose of 2.5 to 7.5 mg was administered after topical anesthesia, and follow-up varied from 8 to 10 months. Results: Subconjunctival RTX showed minimal to no effect on subjective symptoms, clinical features and/or ultrasound images. No serious adverse effects occurred. Conclusion: Further studies are needed to assess the effect of local administration of RTX in scleritis, but our limited observation is not promising.",

author = "Vergouwen, {D. P.C.} and {Ten Berge}, {J. C.} and Naus-Postema, {N. C.} and A. Rothova",

note = "Funding Information: This work was supported by Stichting Lijf en Leven under Grant [number L&L/mon/19-007]. Publisher Copyright: {\textcopyright} 2022 Taylor & Francis Group, LLC.",

year = "2022",

doi = "10.1080/09273948.2022.2029498",

language = "English",

volume = "30",

pages = "1309--1311",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Taylor & Francis Ltd",

number = "6",

}

TY - JOUR

T1 - Subconjunctival Rituximab Administration for the Treatment of Scleritis

AU - Vergouwen, D. P.C.

AU - Ten Berge, J. C.

AU - Naus-Postema, N. C.

AU - Rothova, A.

PY - 2022

Y1 - 2022

N2 - Purpose: Scleritis is a sight-threatening inflammation, which is commonly accompanied by severe complications. Aggressive systemic immunosuppressive treatment, which is frequently needed, can be associated with serious complications, and might therefore be (temporarily) contraindicated. Methods: We report on the outcomes of three patients with severe, active, non-infectious scleritis, refractory or intolerant to systemic treatment, who received subconjunctival rituximab (RTX) injections. A dose of 2.5 to 7.5 mg was administered after topical anesthesia, and follow-up varied from 8 to 10 months. Results: Subconjunctival RTX showed minimal to no effect on subjective symptoms, clinical features and/or ultrasound images. No serious adverse effects occurred. Conclusion: Further studies are needed to assess the effect of local administration of RTX in scleritis, but our limited observation is not promising.

AB - Purpose: Scleritis is a sight-threatening inflammation, which is commonly accompanied by severe complications. Aggressive systemic immunosuppressive treatment, which is frequently needed, can be associated with serious complications, and might therefore be (temporarily) contraindicated. Methods: We report on the outcomes of three patients with severe, active, non-infectious scleritis, refractory or intolerant to systemic treatment, who received subconjunctival rituximab (RTX) injections. A dose of 2.5 to 7.5 mg was administered after topical anesthesia, and follow-up varied from 8 to 10 months. Results: Subconjunctival RTX showed minimal to no effect on subjective symptoms, clinical features and/or ultrasound images. No serious adverse effects occurred. Conclusion: Further studies are needed to assess the effect of local administration of RTX in scleritis, but our limited observation is not promising.

UR - http://www.scopus.com/inward/record.url?scp=85125361266&partnerID=8YFLogxK

U2 - 10.1080/09273948.2022.2029498

DO - 10.1080/09273948.2022.2029498

M3 - Comment/Letter to the editor

C2 - 35171758

AN - SCOPUS:85125361266

SN - 0927-3948

VL - 30

SP - 1309

EP - 1311

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

IS - 6

ER -

Subconjunctival Rituximab Administration for the Treatment of Scleritis

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this